Modular Medical Gets FDA Approval for MODD1 Insulin Pump

Modular Medical, Inc., a technology company specializing in insulin delivery systems, has announced that it received clearance from the U.S. Food and Drug Administration (FDA) to market and sell its MODD1 pump within the United States. The company plans to make the MODD1 commercially available by early 2025, marking a significant milestone in its mission to make diabetes technology more accessible and affordable.

The MODD1 pump is designed to cater to all adults with Type 1 and Type 2 diabetes. Its development was driven by the goal of simplifying diabetes management and expanding access to underserved communities. Historically, the benefits of insulin pumps have been limited to users who are highly motivated, well-insured, and capable of managing complex technology. Modular Medical aims to break these barriers by offering a product that is easier to prescribe, pay for, and use.

Jeb Besser, CEO of Modular Medical, emphasized the company’s commitment to making advanced glycemic control accessible to a broader audience. According to Besser, the existing landscape has seen superior glycemic control primarily among a niche group of sophisticated users due to cost and complexity. Modular Medical's objective is to simplify the process of adopting insulin pump technology, thereby making it less daunting and more widespread.

Paul DiPerna, Chairman and President of Modular Medical, expressed gratitude toward the company's employees and shareholders for their dedication and support. DiPerna reiterated the company's mission of providing "diabetes care for the rest of us" and emphasized the focus on meeting the needs of all patients and clinicians.

The company plans to hold a conference call to discuss the FDA clearance of the MODD1 pump and outline forthcoming steps and milestones. Details regarding the conference call will be provided once they are available.

Modular Medical was founded by Paul DiPerna, a recognized expert in medical devices and microfluidics engineering. Before establishing Modular Medical, DiPerna founded Tandem Diabetes in 2005 and was instrumental in designing its t:slim insulin pump. The company leverages its patented technologies to create insulin delivery systems that balance simplicity with clinical efficacy, aiming to reach a broader population than traditional insulin pumps.

Modular Medical’s overarching mission is to enhance access to optimal glycemic control, extending beyond the so-called "superusers" of current insulin pump technology. The company strives to simplify diabetes care, ensuring that high-quality treatment is within reach for a wide range of individuals.

In summary, Modular Medical’s MODD1 pump is poised to transform the insulin delivery landscape by making advanced glycemic control more accessible and affordable. With FDA clearance secured and commercial availability anticipated in early 2025, the company is set to fulfill its mission of democratizing diabetes care for all.